Zentalis Pharmaceuticals, Inc.
ZNTLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. Valued at $363.8M, ZNTL is a small-cap name in its sector. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Market Cap
$363.8M
Beta
1.93
P/E (TTM)
—
P/E (Fwd)
-3.35
EPS (TTM)
$-1.94
EPS (Fwd)
$-1.53
ROE
-51.9%
ROA
-27.9%
Cash
$211.8M
Total Debt
$38.7M
Free CF
-$81.4M
52W Change
262.4%
Annual Financials
Cash vs Debt
Zentalis Pharmaceuticals, Inc. holds $211.8M in cash against $38.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$81.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -51.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Zentalis Pharmaceuticals, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZNTL.